<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971304</url>
  </required_header>
  <id_info>
    <org_study_id>BBCIC-GCSF-02</org_study_id>
    <nct_id>NCT04971304</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars</brief_title>
  <official_title>An Exploratory Comparative Effectiveness Analysis of Granulocyte Colony Stimulating Factor Originator Products Versus Biosimilars in Real-world Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catherine M. Lockhart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard Pilgrim Health Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biologics &amp; Biosimilars Collective Intelligence Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This comparative effectiveness and descriptive retrospective cohort study will evaluate&#xD;
      safety and effectiveness outcomes among commercially insured adults who received a&#xD;
      granulocyte colony stimulating factor (G-CSF) biosimilar or originator product during the&#xD;
      first cycle of clinical guideline-indicated intermediate or high febrile neutropenia risk&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This comparative effectiveness and descriptive retrospective cohort study includes&#xD;
      commercially insured adults enrolled in one of four health plans participating in the&#xD;
      Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) Distributed Research&#xD;
      Network. The investigators included patients who received a granulocyte colony stimulating&#xD;
      factor (G-CSF) biosimilar or originator product during the first cycle of clinical&#xD;
      guideline-indicated intermediate or high febrile neutropenia risk chemotherapy. The&#xD;
      investigators will collect patient demographics, cancer diagnosis, chemotherapy regimen, and&#xD;
      patterns of G-CSF biosimilar and originator product use. The investigators will follow&#xD;
      patients from first G-CSF exposure until up to six cycles of chemotherapy receipt, death, or&#xD;
      insurance disenrollment. The primary effectiveness outcome is incidence of febrile&#xD;
      neutropenia. Secondary outcomes include incidence of adverse events and trends in product use&#xD;
      over time. The investigators will compare febrile neutropenia incidence between originator&#xD;
      and biosimilar products using inverse probability weighting to control for confounding.&#xD;
      Secondary analyses will examine 'as treated' outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who develop febrile neutropenia</measure>
    <time_frame>Within 30 days of receipt of first chemotherapy</time_frame>
    <description>ICD-9 or ICD-10 codes for inpatient or outpatient visit indicating fever with infection per validated algorithms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who develop G-CSF associated adverse events</measure>
    <time_frame>Within 30 days of receipt of first chemotherapy</time_frame>
    <description>ICD-9 or ICD-10 codes indicating splenic rupture, anaphylaxis, or leukocytosis.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Cancer, Breast</condition>
  <condition>Cancer, Lung</condition>
  <condition>Cancer of Colon</condition>
  <condition>Cancer of Pancreas</condition>
  <condition>Cancer, Ovarian</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>G-CSF originator receipt</arm_group_label>
    <description>Patients receiving filgrastim (Neupogen) or pegfilgrastim (Neulasta) per Health Care Procedural Coding System (HCPCS) J-codes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-CSF biosimilar receipt</arm_group_label>
    <description>Patients receiving filgrastim biosimilars (filgrastim-aafi, filgrastim-sndz, tbo-filgrastim) or pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgrastim-bmez, pegfilgrastim-cbqv) per Health Care Procedural Coding System (HCPCS) J-codes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Receipt of granulocyte-colony stimulating factor</intervention_name>
    <description>Receipt of originator or biosimilar</description>
    <arm_group_label>G-CSF biosimilar receipt</arm_group_label>
    <arm_group_label>G-CSF originator receipt</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with lung, breast, colon, ovarian, pancreatic, testicular, cervical, uterine, or&#xD;
        NHL cancers initiating clinical guideline-indicated intermediate or high neutropenia risk&#xD;
        chemotherapy between March 1, 2015 and December 31, 2019. Study period observation ends by&#xD;
        June 30, 2020 for participant follow-up. A 12-month look-back prior to the study period&#xD;
        (i.e. as early as March 1, 2014) will be used to ensure health plan enrollment, find&#xD;
        incident cancer diagnoses, and provide a description of reference G-CSF utilization before&#xD;
        biosimilar introduction to the US market.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age 20 or older&#xD;
&#xD;
          -  Diagnosis of lung, breast, colon, ovarian, pancreatic, testicular, cervical, uterine,&#xD;
             or NHL cancer&#xD;
&#xD;
          -  Beginning intermediate or high neutropenia risk chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  One inpatient or two outpatient cancer diagnoses at least 30 days apart in the 183&#xD;
             days prior to the Index Date for cancer different from enrolling cancer diagnosis&#xD;
&#xD;
          -  Any of the following in 183 days prior to Index Date:&#xD;
&#xD;
          -  Any chemotherapy or G-CSF product receipt&#xD;
&#xD;
          -  2&lt; medical claims at least 30 days apart for a skilled nursing facility or hospice&#xD;
             care&#xD;
&#xD;
          -  2&lt; diagnoses/procedure codes at least 1 day apart for cancer-related radiotherapy,&#xD;
             bone marrow or stem cell transplant, diagnosis of HIV/AIDS, severe hepatic disease,&#xD;
             chronic kidney disease, or any non-oncology related neutropenia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 24, 2021</last_update_submitted>
  <last_update_submitted_qc>July 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Biologics &amp; Biosimilars Collective Intelligence Consortium</investigator_affiliation>
    <investigator_full_name>Catherine M. Lockhart</investigator_full_name>
    <investigator_title>Executive Director</investigator_title>
  </responsible_party>
  <keyword>colony stimulating factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

